Business
Research confirms high performance of Parsortix
Research confirms high performance of Parsortix.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 2128M\n Angle PLC\n 20 January 2021\n \n \n \n \n \n \n \n For immediate release\n \n \n \n \n 20 January 2021\n \n \n \n \n \n \n \n \n ANGLE plc (\"the Company\")\n \n \n \n \n \n Parsortix system is \"ideal CTC platform for use in clinical trials and clinical patient management\" \n \n \n \n \n \n \n Independent research confirms high performance of Parsortix\n \n \n \n ®\n \n \n \n system in isolating CTCs for downstream analysis\n \n \n \n \n \n \n ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce the publication of new data demonstrating the performance of ANGLE's Parsortix® system in a head-to-head comparison with the leading antibody-based CTC system. \n \n \n \n \n \n Researchers at Western University and Lawson Health Research Institute, Ontario, Canada, investigated the ability of the Parsortix system to harvest circulating tumour cells (CTCs) using blood from healthy volunteers spiked with tumour cells from an epithelial breast cancer cell line and a mesenchymal prostate cancer cell line. \n \n \n \n \n \n The authors report that the Parsortix system could harvest significantly more mesenchymal prostate CTCs than the leading antibody-based CTC system and comparable numbers of epithelial breast CTCs. This is clinically relevant because, during the process of cancer metastases, cancer cells undergo morphological and molecular changes to transition from an epithelial to a mesenchymal phenotype. Although the transition to a mesenchymal phenotype is associated with increased metastatic potential and worse prognosis, many CTC isolation methods, including the leading antibody-based system, only identify cells expressing epithelial markers. These findings provide further evidence that the Parsortix system can isolate and harvest a variety of CTCs, irrespective of their surface antigens, for downstream molecular analysis.\n \n \n \n \n \n Furthermore, unlike the leading antibody-based CTC system, which is used for enumeration, the Parsortix system allowed for the recovery of CTCs for downstream molecular analysis - specifically RNA expression. Rather than simply identifying the presence of CTCs, Parsortix has the ability to inform meaningful clinical decisions and provides a minimally invasive means to monitor...